Eli Lilly acquires Morphic Holding for $3.2bn, bolstering its immunology pipeline with experimental IBD therapies.
Eli Lilly agreed to acquire U.S. biopharma company Morphic Holding for $3.2bn, boosting Lilly's immunology pipeline with experimental therapies for inflammatory bowel disease and other chronic illnesses. Morphic is developing a selective oral small molecule for IBD treatment, with ongoing clinical trials in ulcerative colitis and early-stage trials in Crohn's disease. The deal should close in Q3 2024, subject to conditions.
July 08, 2024
7 Articles